TOCIVID-19 – A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocolTOCIVID-19 - COVID-19 폐렴 환자 치료에서 토실리주맙의 효능 및 내약성에 대한 다기관 연구. 연구 프로토콜Article Published on 2020-11-012022-09-11 Journal: Contemporary clinical trials [Category] MERS, 임상, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome administration ambient Analysis can not co-primary endpoints Cohort complication of COVID-19 COVID-19 COVID-19 pneumonia Critical cytokine Cytokine storm dose Efficacy eligible enrolled EudraCT hospitalized patient hospitalized patients Host immune response humanized monoclonal antibody IL-6 IL-6 receptor include intravenous Intravenous administration Intubated Italian population lethality rate lethality rates multicenter multicentre NCT04317092 oxygen oxygen saturation Patient patients patients with COVID-19 Phase 2 Phase 2 study Pneumonia primary analysis prospective cohort protocol reached receive receptor recombinant humanized monoclonal antibody Registered respiratory respiratory distress Respiratory distress syndrome respiratory impairment Respiratory Support Result Sample Sample size single-arm phase 2 single-arm phase 2 study syndrome the cytokine storm Tocilizumab TOCIVID-19 Tolerability treat Treatment Trial with COVID-19 [DOI] 10.1016/j.cct.2020.106165 PMC 바로가기 [Article Type] Article
COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patientsCOVID-19: SARS-CoV-2 감염 환자의 사이토카인 폭풍 증후군 치료를 위해 IL-6 수용체 길항제 고려Article Published on 2020-11-012022-09-12 Journal: Journal of medical virology [Category] 진단, [키워드] acute respiratory syndrome antagonist clinical trial coronavirus COVID-19 COVID-19 patients Critical cytokine Cytokine storm Cytokine storm syndrome ENhance humanized monoclonal antibody IL-6 receptor IL-6R IL-6R antagonist Mortality Patient patients physician receptor reduce researcher sarilumab SARS-CoV-2 infected patient the cytokine storm therapeutic therapeutic option therapy Tocilizumab [DOI] 10.1002/jmv.26078 PMC 바로가기 [Article Type] Article
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammationArticle Published on 2020-11-012023-07-12 Journal: International Journal of Infectious Diseases [Category] SARS, [키워드] COVID-19 Cytokine release syndrome IL-6 Inflammation SARS-CoV-2 Tocilizumab [DOI] 10.1016/j.ijid.2020.07.078 PMC 바로가기
Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients토실리주맙 챌린지: 입원한 COVID-19 폐렴 환자에서 일련의 사이토카인 폭풍 치료 경험Article Published on 2020-11-012022-09-12 Journal: Journal of medical virology [Category] 진단, [키워드] Administered analyzed C-reactive protein caused Clinical findings Clinical improvement Clinical outcome clinics Computed tomography coronavirus disease COVID-19 COVID-19 pneumonia patient COVID-19 pneumonia patients cytokine response Cytokine storm Diagnosis discharged home dropped evaluated excessive cytokine response faculty Fever Health Hospital stay hospitalized COVID-19 IL-6 inhibitor intensive care İstanbul Laboratory limits normalized novel coronavirus SARS-CoV-2 oxygen saturation Patient patients Pneumonia provide radiological recognize required SARS-CoV-2 significantly Support therapy Thorax Tocilizumab Treatment treatment for COVID-19 Turkey university ventilator [DOI] 10.1002/jmv.26111 PMC 바로가기 [Article Type] Article
Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19Article Published on 2020-11-012023-07-12 Journal: Food and chemical toxicology : an international jo [Category] SARS, [키워드] COVID-19 Endothelial glycocalyx interleukin 6 Myocardial deformation rheumatoid arthritis Tocilizumab [DOI] 10.1016/j.fct.2020.111694 PMC 바로가기
Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study고형 장기 이식 환자의 중증 COVID-19에 대한 Tocilizumab: 일치 코호트 연구Case Reports Published on 2020-11-012022-09-12 Journal: American journal of transplantation : official jou [Category] MERS, SARS, 진단, [키워드] administration age benefit Chronic kidney disease Clinical characteristics clinical research/practice cohort study complication: infectious control group control patient Corticosteroids COVID-19 Efficacy evaluated High dose hospital discharge Hospitalized hypertension identify immune immune regulation immunosuppression/immune modulation Infectious disease Intubated Mortality no difference no significant difference outcome oxygen support Patient randomized study recipient recipients Safe Secondary infection severe COVID-19 severe respiratory symptom significantly higher solid organ transplant SOT subset Tocilizumab Treatment with COVID-19 [DOI] 10.1111/ajt.16314 PMC 바로가기 [Article Type] Case Reports
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment토실리주맙 치료 중 MOG 항체 관련 장애에서 양성 SARS-CoV-2 감염Case Reports Published on 2020-11-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, [키워드] affected anti-IL6 Anti-IL6 receptor Asymptomatic Benign COVID-19 demyelinating disorder disease disorder high risk Infection MOGAD monoclonal antibody Myelin Oligodendrocyte Patient Prevent receptor respiratory SARS-CoV-2 SARS-COV-2 infection subgroup of patient survival rate tested the patient Tocilizumab Treatment treatment with tocilizumab [DOI] 10.1016/j.msard.2020.102592 PMC 바로가기 [Article Type] Case Reports
Outcome of COVID-19 patients with use of Tocilizumab: A single center experienceArticle Published on 2020-11-012023-07-12 Journal: International immunopharmacology [Category] SARS, [키워드] COVID-19 Critically ill Tocilizumab Treatment [DOI] 10.1016/j.intimp.2020.106926 PMC 바로가기
Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report가나의 교육 병원에서 중증 COVID-19 환자의 토실리주맙 사용: 사례 보고Case Reports Published on 2020-10-292022-09-01 Journal: The Pan African Medical Journal [Category] MERS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission Analysis antibody best breathlessness C-reactive protein C-reactive protein (CRP Case report Chain Reaction Chest Chest CT chest CT scan chest pain Clinical outcome Computed tomography coronavirus coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 pneumonia CRP dose drug drug therapy elevated Fever Health hypertensive in some Inflammatory response interleukin-6 intravenous tocilizumab knowledge Laboratory male monoclonal Nasopharyngeal swab nasopharyngeal swab sample on admission outbreak outcome Patient pleuritic Pneumonia polymerase chain polymerase chain reaction positive productive cough receiving receptor respiratory respiratory symptom respiratory symptoms SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Severe COVID-19 pneumonia Spread Standard of care sub-Saharan Africa Teaching tested therapy for COVID-19 Tocilizumab treated treatment with tocilizumab Vaccine worsened [DOI] 10.11604/pamj.supp.2020.37.1.25851 PMC 바로가기 [Article Type] Case Reports
Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort studyResearch Published on 2020-10-292022-10-30 Journal: Journal of Translational Medicine [Category] COVID-19, MERS, SARS, [키워드] administration Admission association AUC benefit blockade Chinese cohort study Concentration conducted confirmed cases coronavirus disease COVID-19 COVID-19 patients Critical cured defined Diagnosis diagnostic disease severity Efficacy elevated Follow-up group Hospital stay IL-6 IL-6 levels IL-6 receptor In-hospital death interleukin-6 IQR median not significantly different outcome Patient patients with SARS-CoV-2 Predictive Preliminary data Registered remained Result retrospective SARS-CoV-2 sensitivity serum Serum IL-6 severity significantly increased specificity survival tested Tocilizumab Treatment [DOI] 10.1186/s12967-020-02571-x PMC 바로가기 [Article Type] Research